Clinical Trials Browser

INDUSTRY × donafenib × Other hematologic neoplasm × Clear all

NCT04402723 2022-12-01

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute